Explore our new preclinical
oncology solutions
Discover our blog articles
Companion Oncology Services: From Target Discovery to Late-Stage Clinical Support
We use a global, multidisciplinary service suite to enrich cancer discovery programmes at every stage. From the very start of a pipeline, we offer:
- Chemoinformatic screening platforms for target and biomarker discovery
- Complete analytical and bioanalytical services for full chemistry support
- A range of in vitro and ex vivo models to facilitate hit-to-lead & high-throughput lead-optimisation screens
These services echo through our oncology studies, enabling biomarker-driven drug development and pharmacological profiling that streamline decision making and reduce risk – all delivered to the exacting quality standards of QIMA Life Sciences.
In vitro Oncology & Immuno-Oncology Platforms
QIMA Life Sciences delivers research solutions that are tailored to the needs of our clients, the mechanisms-of-action of their treatments, and to the therapeutic modality. Leveraging deep expertise in immunology, immuno-oncology, and translational oncology, we conduct pre-clinical and IND-enabling oncology studies via the purpose-built, 900+ m2 Axis Bio facility. Our cell-based assays are built on decades of research and have evolved with the landscape of cancer treatment, and we excel at customising and linking our platforms to provide optimal study designs.
Curated Cancer Cell Line Portfolio
Our oncology capabilities cover all major cancer types, from solid tumours (breast, colorectal, glioblastoma, lung, liver, bladder, prostate, head and neck, pancreatic, melanoma) to hematologic malignancies (leukemia, lymphoma) and we maintain a panel of supplementary non-cancer cell lines for mechanistic and safety assays.
Blue cell lines are of mouse origin. These lists represent only some of our most common translational oncology models, the list is non-exhaustive, and a rare cancer xenograft validation programme is also ongoing. Contact our experts for any cell-line or disease-specific enquiries.
In addition to our portfolio of more than 150 well-characterised lines, we support the validation of client-specified cell lines for both in vitro and xenograft models (flank or orthotopic sites), expanding the scope of tumor models available for oncology research.
Cytotoxicity, Proliferation & Cell Health Assays
Our in vitro oncology platforms provide anti-tumoural efficacy testing and safety profiling at the level of throughput and depth your programme demands. Assay options are available in 2D and 3D formats, and can pair with functional readouts and immunogenicity and safety profiling to enrich data outputs.
Screening approaches include:
- MTT/MTS/XTT assays
- LDH release
- ATP-based assays
- Bioluminescence readouts
- High content counting and microscopy
- [3H]-Thymidine incorporation
- BrdU incorporation
For more translational depth we offer:
- Combination cell health readouts
- Spheroid and soft agar cultures
- Clonogenic assays
- Co-culture models
- Flow cytometry solutions (e.g. apoptosis assays)
- Immunohistochemistry solutions (e.g. Ki-67 staining)
Discover our
oncology-related assays
Functional Molecular and Phenotypic Readouts
A comprehensive catalogue of molecular and cellular biology techniques enhances our preclinical tests, from in vitro functional screens to in vivo biomarker identification, validation, and tracking.
Choose a clinically translatable, ready-to-run assay from our library, or collaborate with our scientists to develop bespoke workflows for your specific oncology modality.
Nucleic acid solutions
- PCR and qPCR
- siRNA knockdown
- CRISPR/Cas knockout
- -omics services
- Gene expression profiling
- DNA damage assay
Protein analytics
- Western blotting
- ELISAs and activity assays
- ELISpot
- Multiplex assay panels
- Sequential immunofluorescence staining
- Surface and intracellular flow cytometry staining
- -omics services
Functional phenotypes
- Tumour motility and invasion
- Tumour migration
- Cell differentiation assays
- Endocytosis and uptake assays
- Barrier permeability models
- Tube formation
Immuno-Oncology Readouts and Safety Profiling
Understanding the interaction between treatments, tumours, and immune cells is critical for oncology drug discovery. QIMA Life Sciences provide assays for testing the innate and adaptive immune responses to treatments in blood and tissues, and for investigating tumour-immune interactions in co-culture systems.
Immune cells:
- Neutrophils
- Basophils
- Eosinophils
- Monocytes
- Macrophages
- Dendritic cells
- T cells
- Regulatory T cells
Assays:
- PMN, Macrophage, Dendritic Cell activation
- Immune-mediated tumour kill assays
- Phagocytosis
- PMN oxidative burst
- M1 or M2 polarization and switch
- Chemotaxis and invasion
- T cell immunophenotyping
- Proliferation
- Cytokine and chemokine release
Immunocytes can be freshly drawn from volunteers, or sourced from biobanks and our assays can be expanded with various additional functional readouts.
Learn more about our
Immune Response Assays
